share_log

HC Wainwright & Co. Maintains Buy on BriaCell Therapeutics, Lowers Price Target to $20

HC Wainwright & Co. Maintains Buy on BriaCell Therapeutics, Lowers Price Target to $20

HC Wainwright & Co.维持对BriaCell Therapeutics的买入,将目标价下调至20美元
Benzinga ·  2023/10/03 12:03

HC Wainwright & Co. analyst Emily Bodnar maintains BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and lowers the price target from $25 to $20.

HC Wainwright&Co.分析师Emily Bodnar维持BriaCell Treateutics(纳斯达克:BCTX)的买入,并将目标价从25美元下调至20美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发